Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Change in Receivables: 2020-2025

Historic Change in Receivables for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -$254,000.

  • Insight Molecular Diagnostics' Change in Receivables fell 304.84% to -$254,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $49,000, marking a year-over-year increase of 119.29%. This contributed to the annual value of $1.1 million for FY2024, which is 1135.78% up from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Change in Receivables of -$254,000 as of Q3 2025, which was up 91.61% from -$3.0 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Change in Receivables ranged from a high of $1.9 million in Q1 2025 and a low of -$3.0 million during Q2 2025.
  • Its 3-year average for Change in Receivables is -$30,455, with a median of -$76,000 in 2024.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Change in Receivables skyrocketed by 6,585.71% in 2024, and later plummeted by 3,884.21% in 2025.
  • Quarterly analysis of 5 years shows Insight Molecular Diagnostics' Change in Receivables stood at $405,000 in 2021, then tumbled by 94.57% to $22,000 in 2022, then fell by 4.55% to $21,000 in 2023, then soared by 6,585.71% to $1.4 million in 2024, then slumped by 304.84% to -$254,000 in 2025.
  • Its Change in Receivables was -$254,000 in Q3 2025, compared to -$3.0 million in Q2 2025 and $1.9 million in Q1 2025.